Literature DB >> 4634038

Phase I clinical trial of a new antitumor agent, 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene- -D-glucopyranoside) (NSC-141540; VP-16-213).

N I Nissen, V Larsen, H Pedersen, K Thomsen.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4634038

Source DB:  PubMed          Journal:  Cancer Chemother Rep        ISSN: 0069-0112


× No keyword cloud information.
  14 in total

Review 1.  Chemotherapy in malignant mesothelioma: a review.

Authors:  A Krarup-Hansen; H H Hansen
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

2.  Phase II protocol for the evaluation of new treatments in patients with advanced gastric carcinoma: results of ECOG 5282.

Authors:  Y Novik; L M Ryan; D G Haller; R Asbury; J P Dutcher; A Schutt
Journal:  Med Oncol       Date:  1999-12       Impact factor: 3.064

Review 3.  VP16-213 (etoposide). A critical review of its activity.

Authors:  F Cavalli
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 4.  The clinical pharmacology of VM26 and VP16-213. A brief overview.

Authors:  P J Creaven
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 5.  Antineoplastic drugs: clinical pharmacology and therapeutic use.

Authors:  R A Bender; L A Zwelling; J H Doroshow; G Y Locker; K R Hande; D S Murinson; M Cohen; C E Myers; B A Chabner
Journal:  Drugs       Date:  1978-07       Impact factor: 9.546

Review 6.  The podophyllotoxin derivatives VP16-213 and VM26.

Authors:  B F Issell
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 7.  Current development of podophyllotoxins.

Authors:  R Canetta; P Hilgard; S Florentine; P Bedogni; L Lenaz
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 8.  Cancer chemotherapy: past, present, and future--Part I.

Authors:  J C Wright
Journal:  J Natl Med Assoc       Date:  1984-08       Impact factor: 1.798

9.  Etoposide as a single agent in relapsed advanced lymphomas. A phase II study.

Authors:  R E Taylor; T J McElwain; A Barrett; M J Peckham
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

10.  Pharmacokinetics of VP16-213 in Lewis lung carcinoma bearing mice.

Authors:  T Colombo; M Broggini; L Torti; E Erba; M D'Incalci
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.